Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly \[except for a loading dose of 675 mg for CM patients\] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients
Epistemonikos ID: b0bbf8d97e40b9ffe4a170dc39d9b01601990aca
First added on: May 21, 2024